Genprex, Inc. announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This strategic partnership aims to leverage Roche's assay development expertise and a previously FDA Breakthrough Device Designated TROP2 antibody to refine patient identification, potentially shortening recruitment times and enabling more personalized treatment. Genprex anticipates completing validation studies by late 2026 for subsequent integration into its NSCLC clinical program.

Karyopharm Therapeutics is exploring strategic alternatives and potential financing transactions with Centerview Partners to extend its cash runway and maximize stakeholder value. This corporate update follows mixed clinical news, including the failure of its Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer to meet its primary endpoint, and plans for an August 2026 sNDA submission for accelerated approval of selinexor in myelofibrosis, which is subject to further FDA discussions regarding data for traditional approval conversion.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. Concurrently, the company is exploring strategic alternatives, including potential partnerships, to enhance stockholder value, while also evaluating its cash runway and clinical development timelines.

Lisata Therapeutics, Inc. terminated its merger agreement with Kuva Labs Inc. after Kuva failed to obtain sufficient financing for the tender offer. Kuva is obligated to pay Lisata a $2 million termination fee, and Lisata reserves rights to seek further damages. Lisata's Board will now assess strategic options to enhance stockholder value, including reverse mergers, asset sales, or dissolution, with no assurance of a successful outcome.

Organon & Co. is proceeding with its merger with Sun Pharmaceutical Holdings USA, Inc. A lawsuit was filed alleging incomplete disclosures in the definitive proxy statement, seeking to enjoin the stockholder vote. To avoid delays and litigation risks, Organon voluntarily supplemented the proxy statement, denying the claims' merit. The Board continues to evaluate strategic alternatives, including Sun Pharma's proposal, while considering execution risks associated with other options.

NextCure, Inc. announced a definitive merger agreement with Avere Therapeutics, Inc., under which Avere will become a wholly-owned subsidiary and its stockholders will own approximately 98.11% of the combined entity. The transaction includes a private placement financing for Avere, expected to raise at least $150 million, which is a condition for the merger's closing.

Genprex announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This patent strengthens the company's intellectual property portfolio, providing crucial protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. This expands on previously granted patents for REQORSA in other major markets.